Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2022

View Archived Issues

Nektar Therapeutics presents preclinical data on NKTR-255

KSHN-001034, a novel prodrug that delivers higher fulvestrant concentrations

BLU-222 shows efficacy in CCNE1-amplified ovarian cancer models

Chinese researchers divulge new compounds for cancer

New YAP1/TEAD interaction inhibitors disclosed by SpringWorks Therapeutics and collaborators

Humanwell Healthcare presents new P2X3 receptor antagonists

University of Texas System identifies CBP and/or p300 inhibitors

Medy-Tox patents new BTK inhibitors

Herantis reports blood-brain barrier penetration data with HER-096 in dogs

AT-0174 IDO/TDO dual inhibitor shows promise for treating platinum-resistant NSCLC

Allogeneic NK-cell therapy CAT-179 useful for controlling HER2-positive tumors

Study finds targets of T-cell response in multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...